Electronic drug alert program reduces adverse events

An electronic drug safety alert program within an accountable care organization (ACO) can go a long way regarding patient safety, according to a study conducted by the clinical pharmacy services department at Marshfield Clinic.

The Marshfield, Wisc. organization designed a drug safety alert program (DSP) to provide clinicians prescribing drugs with timely and clinically meaningful medication safety information through the EHR that has an electronic prescribing platform.

The clinic implemented an alert system in EHRs that presents clinicians with up-to-date drug information to help reduce the number of drug-related adverse events. To avoid alert fatigue, the system packages alerts in a report that aggregates all patients who have been prescribed a specific medication rather than sending alerts on individual patients. This ensures that providers are only given the information they need and encourages them to integrate the alerts into their care plans.  

The first year of the DSAP program targeted six medication safety concerns, according to the article published in the Journal of Managed Care & Specialty Pharmacy. In total, approximately 10,000 potential adverse events were identified and approximately 8,000 were resolved by changing prescriptions after the EHR issued an alert.

"A goal of this project was to partner with the prescriber in the overall care of the patient," said Sara Griesbach, PharmD, director of clinical pharmacy services at Marshfield Clinic. "This program was created to identify drug alerts with potential to impact a large patient population that may require intervention to decrease the risk for adverse drug events."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.